Personalized treatment for cancer with genetic fingerprints
 
Geneva:
+4122 840 33 34
 
Moscow:
+7(903)720 80 57

Personalizing cancer treatment with genetic fingerprint

Not all cancers are equally lethal: cancer in your prostate means a longer survival rate than a malignancy in your brain, for example. But even prostate cancer comes in multiple flavors ranging from manageable to very bad. By analyzing the mutated genome of a tumor, doctors can now pinpoint whether a cancer is sensitive to a certain chemotherapy, or one that doesn’t respond at all to current treatments. Knowing the subtype might mean jumping directly to a clinical trial that could save your life.

Cancer is a disease of the genome. It arises when genes involved in promoting or suppressing cell growth sustain mutations that disturb the normal stop and go signals. There are more than 100 different types of cancer, most of which derive their names and current treatment based on their tissue of origin—breast, colon, or brain, for example. But because of advances in DNA sequencing and analysis, that soon may be about to change.

A new method to take the DNA fingerprint of individual cancer cells is uncovering the true extent of cancer’s genetic diversity. A single cancer cell may help oncologists anticipate tumor growth. A genetic “fingerprint” taken from a cancerous cell can reveal the extent of the cancer’s genetic diversity — its “family tree.” By highlighting key mutations, the method could help doctors develop more effective, personalized therapies.

There is a huge potential to identify key genomic changes shared by certain subsets of tumors, regardless of where they arise in the body. Such information is vital to our efforts to develop more individualized approaches for helping people with cancer—called personalized medicine, or precision medicine. For example, if a patient’s tumor has a genomic fingerprint that indicates it is likely to spread to other areas of the body, or metastasize, doctors may suggest a more aggressive treatment strategy than they would for someone whose tumor had a different profile.

Genomic information might also help us figure out if a drug originally approved for use in one type of cancer might be useful in treating other types. For example, if a drug works for colon cancer, it might also work for a lung cancer with a similar genetic fingerprint.

Comments
Articles
Patient registration form
Topics
Examination Incorpore
nutrition
oncology
prevention
cancer
dermatology
age management
Anti-aging
detoxification
skin
heavy metal
diagnosis
cardiology
immunology
stem cells
weight management
oncology treatment
liver detox
DNA
Genetics
allergy
pain
Fertility
Examination partner centres
gastroenterology
covid19
weight loss
cosmetology
liver
infertility
chelation
Sleep
gynecology
urology
radiology
neurology
check-up
skincare
pregnancy
Hepatitis C
rehabilitation
headache
breast cancer
candida
arsenic
anti-aging
obstetrics
joints
immune system
Дерматология
heart MRI
immunotherapy
NAD+
Blood pressure
mesotherapy
probiotics
Apnea
tinnitus
ulcer
abdominal pain
pancreas
research
sexuality
beau-rivage
nutrigenomics
migraine
menopause
telomere
gastritis
flu vaccine
regeneration
PRP
andropause
light therapy
excimer laser
psoriasis
hyaluronic acid
sugar
obstertics
rhesus factor
Allergology
preventiion
gastroscopy
brain surgery awake
mastectomy
digestion
mammography
cellmen
cellcosmet
herniated disc
flu
magnesium
R-loops
Omega-3
shoulder
hand
intestinal flora
depression
iron
second opinion
food intolerances
reflexology
food
vitamin b12
mercury
water
erectile dysfunction
back pain
hip
knee
beauty
exercise
sports
cholesterol
stress
vitamin K
narcosis
diabetes
cellulite
acnea
migraines
chronic headaches
diet
oncoloy
reconstruction
blood test
endometriosis
acne
LED therapy
biopsy
liquid biopsy
oral checkup
propofole
dermatitis
hormones
general surgery
nephrology
kidney
ophthalmology
plastic surgery
lungs
pneumology
proctology
pomegranate
rheumatology
orthopedics
colonoscopy
endocrinology
Treatment programs